Arrowhead Pharmaceuticals Shifts Focus to Plozasiran, Deprioritizes Zodasiran in Cardiometabolic Drug Development

1. Arrowhead Pharmaceuticals has decided to focus on plozasiran, an RNAi therapy targeting APOC3, and deprioritize zodasiran, which targets ANGPTL3, in its cardiometabolic drug pipeline.
2. Plozasiran is seen as a more promising candidate, with compelling data in three settings, and is expected to be "launch-ready" in 2025.
3. Zodasiran, an LDL cholesterol drug, faces significant competition in the market, whereas plozasiran addresses unmet needs in treating high triglycerides.
4. Arrowhead aims to find a partner for zodasiran, which is still believed to have potential in the LDL cholesterol space.
5. The company is pushing ahead with trials for plozasiran, including a phase 3 cardiovascular outcomes study, to position it for market launch in 2025.